首页> 外文期刊>Molecular biology reports >Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine patients in real clinical practice
【24h】

Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine patients in real clinical practice

机译:偏头痛的血清CGRP,VIP和PACAP有用性:实际临床实践中慢性偏头痛患者的病例对照研究

获取原文
获取原文并翻译 | 示例
           

摘要

Calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypetide-38 (PACAP-38) have relevant roles in migraine pathophysiology. Their serum levels have been proposed as biomarkers for migraine. Our aim was to assess their diagnostic value in real clinical practice in a cohort of chronic migraine (CM), episodic migraine (EM) and healthy controls (HC). We recruited subjects with CM, EM and HC at two medical centers. Blood samples were drawn under fasting conditions in the interictal period, immediately centrifuged and stored at - 80 oC. Serum levels were determined by ELISA. Neuropeptide levels, the effect of preventatives, correlations with clinical and demographic variables, and their diagnostic value were studied among clinical categories. 296 age- and sex-matched subjects (101 CM, 98 EM and 97 HC) were included. All three neuropeptide serum levels were higher in CM [median and IQ for CGRP = 18.023 pg/ml (14.4-24.7); VIP = 121.732 pg/ml (48.72-186.72) and PACAP = 204.931 pg/ml (101.08-597.64)] vs EM [CGRP = 14.659 pg/ml (10.29-17.45); VIP = 75.603 pg/ml (28.722-107.10); and PACAP = 94.992 pg/ml (65.77-128.48)] and vs HC [CGRP = 13.988 pg/ml (10.095-17.87); VIP = 84.685 pg/ml (35.32-99.79), and PACAP = 103.142 pg/ml (59.42-123.97)]. Using multinomial modeling, only VIP (OR 1.011, 95% CI 1.003-1.018, p = 0.005) and PACAP (OR 1.003, 95% CI 1.001-1.005, p = 0.002) increased the risk for CM, but not for EM. CGRP did not predict CM or EM. This model could correctly classify only 62/101 (61.38%) of CM, 75/98 (76.53%) of EM, and 5/97 (4.12%) of HC [globally 147/296 (49.8%)]. Individually, PACAP performed the best for classifying clinical categories [global accuracy 150/296 (50.67%)]. In CM, neuropeptide levels were higher in those OnaBT-treated than in no-treated patients. Although interictal serum CGRP and VIP were higher in CM than both EM or HC, their utility to discriminate migraine categories was low. Contrary to other studies, PACAP serum levels were also higher in CM than in EM or HC and had more discriminative capability to distinguish CM from EM and HC. Further investigation is needed for determination technique standardization.
机译:Calcitonin基因相关的肽(CGRP),血管活性肠肽(VIP)和垂体腺苷酸环酶活化息肉-38(PACAP-38)在偏头痛病理学中具有相关的作用。他们的血清水平被提出为偏头痛的生物标志物。我们的目的是评估其在慢性偏头痛(CM),癫痫术(EM)和健康对照(HC)队列的真实临床实践中的诊断价值。我们在两个医疗中心招募了CM,EM和HC的主题。在嵌入时间内的禁用条件下拉出血液样品,立即离心并储存在-80℃。血清水平由ELISA确定。神经肽水平,预防性的效果,与临床和人口变量的相关性,以及临床类别的诊断价值。 296年龄和性别匹配的受试者(101厘米,98个和97 HC)。所有三种神经肽血清水平均以CM [中位数和IQ为CGRP = 18.023pg / ml(14.4-24.7); vip = 121.732 pg / ml(48.72-186.72)和PACAP = 204.931 pg / ml(101.08-597.64)] Vs em [CGRP = 14.659 pg / ml(10.29-17.45); vip = 75.603 pg / ml(28.722-107.10);和Pacap = 94.992 pg / ml(65.77-128.48)和vs hc [cgrp = 13.988 pg / ml(10.095-17.87); vip = 84.685 pg / ml(35.32-99.79),acap = 103.142 pg / ml(59.42-123.97)]。使用多项式建模,仅VIP(或1.011,95%CI 1.003-1.018,P = 0.005)和PACAP(或1.003,95%CI 1.001-1.005,P = 0.002)增加了CM的风险,但不适用于EM。 CGRP没有预测CM或EM。该模型可以正确分类仅62/101(61.38%)的厘米,75/98%(76.53%),以及5/97(4.12%)的HC [全球147/296(49.8%)]。单独,PACAP对分类临床类别进行最佳方式[全球精度150/296(50.67%)]。在厘米中,在没有治疗的患者的那些妥涂治疗中,神经肽水平较高。虽然嵌入式血清CGRP和VIP的CM或HC均高于EM或HC,但它们鉴别偏头痛类别的实用性低。与其他研究相反,PACAP血清水平的CM含量比在EM或HC中也高,并且具有更大的辨别能力来区分CM和HC。确定技术标准化需要进一步调查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号